

**TOXICOLOGICAL PROFILE FOR  
METHYL PARATHION**

Prepared for:

**U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES  
Public Health Service  
Agency for Toxic Substances and Disease Registry**

September 2001

## **DISCLAIMER**

The use of company or product name(s) is for identification only and does not imply endorsement by the Agency for Toxic Substances and Disease Registry.

## **UPDATE STATEMENT**

Toxicological profiles are revised and republished as necessary, but no less than once every three years. For information regarding the update status of previously released profiles, contact ATSDR at:

Agency for Toxic Substances and Disease Registry  
Division of Toxicology/Toxicology Information Branch  
1600 Clifton Road NE, E-29  
Atlanta, Georgia 30333



## FOREWORD

This toxicological profile is prepared in accordance with guidelines\* developed by the Agency for Toxic Substances and Disease Registry (ATSDR) and the Environmental Protection Agency (EPA). The original guidelines were published in the *Federal Register* on April 17, 1987. Each profile will be revised and republished as necessary.

The ATSDR toxicological profile succinctly characterizes the toxicologic and adverse health effects information for the hazardous substance described therein. Each peer-reviewed profile identifies and reviews the key literature that describes a hazardous substance's toxicologic properties. Other pertinent literature is also presented, but is described in less detail than the key studies. The profile is not intended to be an exhaustive document; however, more comprehensive sources of specialty information are referenced.


The focus of the profiles is on health and toxicologic information; therefore, each toxicological profile begins with a public health statement that describes, in nontechnical language, a substance's relevant toxicological properties. Following the public health statement is information concerning levels of significant human exposure and, where known, significant health effects. The adequacy of information to determine a substance's health effects is described in a health effects summary. Data needs that are of significance to protection of public health are identified by ATSDR and EPA.

Each profile includes the following:

- (A) The examination, summary, and interpretation of available toxicologic information and epidemiologic evaluations on a hazardous substance to ascertain the levels of significant human exposure for the substance and the associated acute, subacute, and chronic health effects;
- (B) A determination of whether adequate information on the health effects of each substance is available or in the process of development to determine levels of exposure that present a significant risk to human health of acute, subacute, and chronic health effects; and
- (C) Where appropriate, identification of toxicologic testing needed to identify the types or levels of exposure that may present significant risk of adverse health effects in humans.

The principal audiences for the toxicological profiles are health professionals at the Federal, State, and local levels; interested private sector organizations and groups; and members of the public.

This profile reflects ATSDR's assessment of all relevant toxicologic testing and information that has been peer-reviewed. Staff of the Centers for Disease Control and Prevention and other Federal scientists have also reviewed the profile. In addition, this profile has been peer-reviewed by a nongovernmental panel and was made available for public review. Final responsibility for the contents and views expressed in this toxicological profile resides with ATSDR.



Jeffrey P. Koplan, M.D., M.P.H.  
Administrator  
Agency for Toxic Substances and  
Disease Registry

### \*Legislative Background

The toxicological profiles are developed in response to the Superfund Amendments and Reauthorization Act (SARA) of 1986 (Public law 99-499) which amended the Comprehensive Environmental Response, Compensation, and Liability Act of 1980 (CERCLA or Superfund). This public law directed ATSDR to prepared toxicological profiles for hazardous substances most commonly found at facilities on the CERCLA National Priorities List and that pose the most significant potential threat to human health, as determined by ATSDR and the EPA. The availability of the revised priority list of 275 hazardous substances was announced in the *Federal Register* on November 17, 1997 (62 FR 61332). For prior versions of the list of substances, see *Federal Register* notices dated April 29, 1996 (61 FR 18744); April 17, 1987 (52 FR 12866); October 20, 1988 (53 FR 41280); October 26, 1989 (54 FR 43619); October 17, 1990 (55 FR 42067); October 17, 1991 (56 FR 52166); October 28, 1992 (57 FR 48801); and February 28, 1994 (59 FR 9486). Section 104(i)(3) of CERCLA, as amended, directs the Administrator of ATSDR to prepare a toxicological profile for each substance on the list.

## QUICK REFERENCE FOR HEALTH CARE PROVIDERS

Toxicological Profiles are a unique compilation of toxicological information on a given hazardous substance. Each profile reflects a comprehensive and extensive evaluation, summary, and interpretation of available toxicologic and epidemiologic information on a substance. Health care providers treating patients potentially exposed to hazardous substances will find the following information helpful for fast answers to often-asked questions.

---

### *Primary Chapters/Sections of Interest*

**Chapter 1: Public Health Statement:** The Public Health Statement can be a useful tool for educating patients about possible exposure to a hazardous substance. It explains a substance's relevant toxicologic properties in a nontechnical, question-and-answer format, and it includes a review of the general health effects observed following exposure.

**Chapter 2: Relevance to Public Health:** The Relevance to Public Health Section evaluates, interprets, and assesses the significance of toxicity data to human health.

**Chapter 3: Health Effects:** Specific health effects of a given hazardous compound are reported by *type of health effect* (death, systemic, immunologic, reproductive), by *route of exposure*, and by *length of exposure* (acute, intermediate, and chronic). In addition, both human and animal studies are reported in this section.

**NOTE:** Not all health effects reported in this section are necessarily observed in the clinical setting. Please refer to the Public Health Statement to identify general health effects observed following exposure.

**Pediatrics:** Four new sections have been added to each Toxicological Profile to address child health issues:

<b>Section 1.6</b>	<b>How Can (Chemical X) Affect Children?</b>
<b>Section 1.7</b>	<b>How Can Families Reduce the Risk of Exposure to (Chemical X)?</b>
<b>Section 3.7</b>	<b>Children's Susceptibility</b>
<b>Section 6.6</b>	<b>Exposures of Children</b>

**Other Sections of Interest:**

<b>Section 3.8</b>	<b>Biomarkers of Exposure and Effect</b>
<b>Section 3.11</b>	<b>Methods for Reducing Toxic Effects</b>

---

### *ATSDR Information Center*

**Phone:** 1-888-42-ATSDR or (404) 639-6357    **Fax:** (404) 639-6359  
**E-mail:** [atsdric@cdc.gov](mailto:atsdric@cdc.gov)    **Internet:** <http://www.atsdr.cdc.gov>

The following additional material can be ordered through the ATSDR Information Center:

*Case Studies in Environmental Medicine: Taking an Exposure History*—The importance of taking an exposure history and how to conduct one are described, and an example of a thorough exposure history is provided. Other case studies of interest include *Reproductive and Developmental Hazards; Skin Lesions and Environmental Exposures; Cholinesterase-Inhibiting Pesticide Toxicity*; and numerous chemical-specific case studies.

*Managing Hazardous Materials Incidents* is a three-volume set of recommendations for on-scene (prehospital) and hospital medical management of patients exposed during a hazardous materials incident. Volumes I and II are planning guides to assist first responders and hospital emergency department personnel in planning for incidents that involve hazardous materials. Volume III—*Medical Management Guidelines for Acute Chemical Exposures*—is a guide for health care professionals treating patients exposed to hazardous materials.

*Fact Sheets (ToxFAQs)* provide answers to frequently asked questions about toxic substances.

---

### ***Other Agencies and Organizations***

*The National Center for Environmental Health (NCEH)* focuses on preventing or controlling disease, injury, and disability related to the interactions between people and their environment outside the workplace. *Contact:* NCEH, Mailstop F-29, 4770 Buford Highway, NE, Atlanta, GA 30341-3724 • Phone: 770-488-7000 • FAX: 770-488-7015.

*The National Institute for Occupational Safety and Health (NIOSH)* conducts research on occupational diseases and injuries, responds to requests for assistance by investigating problems of health and safety in the workplace, recommends standards to the Occupational Safety and Health Administration (OSHA) and the Mine Safety and Health Administration (MSHA), and trains professionals in occupational safety and health. *Contact:* NIOSH, 200 Independence Avenue, SW, Washington, DC 20201 • Phone: 800-356-4674 or NIOSH Technical Information Branch, Robert A. Taft Laboratory, Mailstop C-19, 4676 Columbia Parkway, Cincinnati, OH 45226-1998 • Phone: 800-35-NIOSH.

*The National Institute of Environmental Health Sciences (NIEHS)* is the principal federal agency for biomedical research on the effects of chemical, physical, and biologic environmental agents on human health and well-being. *Contact:* NIEHS, PO Box 12233, 104 T.W. Alexander Drive, Research Triangle Park, NC 27709 • Phone: 919-541-3212.

---

### ***Referrals***

*The Association of Occupational and Environmental Clinics (AOEC)* has developed a network of clinics in the United States to provide expertise in occupational and environmental issues. *Contact:* AOEC, 1010 Vermont Avenue, NW, #513, Washington, DC 20005 • Phone: 202-347-4976 • FAX: 202-347-4950 • e-mail: [AOEC@AOEC.ORG](mailto:AOEC@AOEC.ORG) • Web Page: <http://www.aoec.org/>.

*The American College of Occupational and Environmental Medicine (ACOEM)* is an association of physicians and other health care providers specializing in the field of occupational and environmental medicine. *Contact:* ACOEM, 55 West Seegers Road, Arlington Heights, IL 60005 • Phone: 847-818-1800 • FAX: 847-818-9266.



## CONTRIBUTORS

### CHEMICAL MANAGER(S)/AUTHORS(S):

Jewell D. Wilson, Ph.D.  
ATSDR, Division of Toxicology, Atlanta, GA

Joan Colman, Ph.D.  
David Wohlers, Ph.D.  
Syracuse Research Corporation, North Syracuse, NY

Cheryl Sutton, Ph.D.  
Syracuse Research Corporation, Arlington, VA

### THE PROFILE HAS UNDERGONE THE FOLLOWING ATSDR INTERNAL REVIEWS:

1. Health Effects Review. The Health Effects Review Committee examines the health effects chapter of each profile for consistency and accuracy in interpreting health effects and classifying end points.
2. Minimal Risk Level Review. The Minimal Risk Level Workgroup considers issues relevant to substance-specific minimal risk levels (MRLs), reviews the health effects database of each profile, and makes recommendations for derivation of MRLs.
3. Data Needs Review. The Research Implementation Branch reviews data needs sections to assure consistency across profiles and adherence to instructions in the Guidance.



## PEER REVIEW

A peer review panel was assembled for methyl parathion. The panel consisted of the following members:

1. Donald Morgan, M.D./Ph.D., Private Consultant, Cedar Rapids, Iowa;
2. Shane Que Hee, Ph.D., Department of Environmental Health Sciences, UCLA School of Public Health, Los Angeles, California;
3. Michael Utidjian, M.D., Private Consultant, Wayne, New Jersey.

These experts collectively have knowledge of methyl parathion's physical and chemical properties, toxicokinetics, key health end points, mechanisms of action, human and animal exposure, and quantification of risk to humans. All reviewers were selected in conformity with the conditions for peer review specified in Section 104(I)(13) of the Comprehensive Environmental Response, Compensation, and Liability Act, as amended.

Scientists from the Agency for Toxic Substances and Disease Registry (ATSDR) have reviewed the peer reviewers' comments and determined which comments will be included in the profile. A listing of the peer reviewers' comments not incorporated in the profile, with a brief explanation of the rationale for their exclusion, exists as part of the administrative record for this compound. A list of databases reviewed and a list of unpublished documents cited are also included in the administrative record.

The citation of the peer review panel should not be understood to imply its approval of the profile's final content. The responsibility for the content of this profile lies with the ATSDR.



## CONTENTS

FOREWORD .....	v
QUICK REFERENCE FOR HEALTH CARE PROVIDERS .....	vii
CONTRIBUTORS .....	ix
PEER REVIEW .....	xi
LIST OF FIGURES .....	xvii
LIST OF TABLES .....	xix
1. PUBLIC HEALTH STATEMENT .....	1
1.1 WHAT IS METHYL PARATHION? .....	1
1.2 WHAT HAPPENS TO METHYL PARATHION WHEN IT ENTERS THE ENVIRONMENT? .....	2
1.3 HOW MIGHT I BE EXPOSED TO METHYL PARATHION? .....	2
1.4 HOW CAN METHYL PARATHION ENTER AND LEAVE MY BODY? .....	4
1.5 HOW CAN METHYL PARATHION AFFECT MY HEALTH? .....	4
1.6 HOW CAN METHYL PARATHION AFFECT CHILDREN? .....	5
1.7 HOW CAN FAMILIES REDUCE THE RISK OF EXPOSURE TO METHYL PARATHION? .....	6
1.8 IS THERE A MEDICAL TEST TO DETERMINE WHETHER I HAVE BEEN EXPOSED TO METHYL PARATHION? .....	8
1.9 WHAT RECOMMENDATIONS HAS THE FEDERAL GOVERNMENT MADE TO PROTECT HUMAN HEALTH? .....	9
1.10 WHERE CAN I GET MORE INFORMATION? .....	10
2. RELEVANCE TO PUBLIC HEALTH .....	11
2.1 BACKGROUND AND ENVIRONMENTAL EXPOSURES TO METHYL PARATHION IN THE UNITED STATES .....	11
2.2 SUMMARY OF HEALTH EFFECTS .....	13
2.3 MINIMAL RISK LEVELS .....	17
3. HEALTH EFFECTS .....	19
3.1 INTRODUCTION .....	19
3.2 DISCUSSION OF HEALTH EFFECTS BY ROUTE OF EXPOSURE .....	19
3.2.1 Inhalation Exposure .....	21
3.2.1.1 Death .....	21
3.2.1.2 Systemic Effects .....	24
3.2.1.3 Immunological and Lymphoreticular Effects .....	25
3.2.1.4 Neurological Effects .....	25
3.2.1.5 Reproductive Effects .....	27
3.2.1.6 Developmental Effects .....	27
3.2.1.7 Cancer .....	27
3.2.2 Oral Exposure .....	27
3.2.2.1 Death .....	27

3.2.2.2	Systemic Effects	29
3.2.2.3	Immunological and Lymphoreticular Effects	48
3.2.2.4	Neurological Effects	49
3.2.2.5	Reproductive Effects	53
3.2.2.6	Developmental Effects	53
3.2.2.7	Cancer	55
3.2.3	Dermal Exposure	56
3.2.3.1	Death	56
3.2.3.2	Systemic Effects	58
3.2.3.3	Immunological and Lymphoreticular Effects	58
3.2.3.4	Neurological Effects	58
3.2.3.5	Reproductive Effects	59
3.2.3.6	Developmental Effects	59
3.2.3.7	Cancer	60
3.2.4	Other Routes of Exposure	60
3.3	GENOTOXICITY	61
3.4	TOXICOKINETICS	67
3.4.1	Absorption	67
3.4.1.1	Inhalation Exposure	67
3.4.1.2	Oral Exposure	68
3.4.1.3	Dermal Exposure	69
3.4.2	Distribution	70
3.4.2.1	Inhalation Exposure	70
3.4.2.2	Oral Exposure	70
3.4.2.3	Dermal Exposure	71
3.4.2.4	Other Routes of Exposure	71
3.4.3	Metabolism	72
3.4.4	Elimination and Excretion	75
3.4.4.1	Inhalation Exposure	75
3.4.4.2	Oral Exposure	75
3.4.4.3	Dermal Exposure	76
3.4.4.4	Other Routes of Exposure	77
3.4.5	Physiologically Based Pharmacokinetic (PBPK)/Pharmacodynamic (PD) Models	77
3.5	MECHANISMS OF ACTION	80
3.5.1	Pharmacokinetic Mechanisms	80
3.5.2	Mechanisms of Toxicity	81
3.5.3	Animal-to-Human Extrapolations	83
3.6	ENDOCRINE DISRUPTION	84
3.7	CHILDREN'S SUSCEPTIBILITY	87
3.8	BIOMARKERS OF EXPOSURE AND EFFECT	91
3.8.1	Biomarkers Used to Identify or Quantify Exposure to Methyl Parathion	92
3.8.2	Biomarkers Used to Characterize Effects Caused by Methyl Parathion	93
3.9	INTERACTIONS WITH OTHER CHEMICALS	95
3.10	POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE	96
3.11	METHODS FOR REDUCING TOXIC EFFECTS	97
3.11.1	Reducing Peak Absorption Following Exposure	98
3.11.2	Reducing Body Burden	99
3.11.3	Interfering with the Mechanism of Action for Toxic Effects	99
3.12	ADEQUACY OF THE DATABASE	100
3.12.1	Existing Information on Health Effects of Methyl Parathion	100

3.12.2	Identification of Data Needs	102
3.12.3	Ongoing Studies	111
4.	CHEMICAL AND PHYSICAL INFORMATION	113
4.1	CHEMICAL IDENTITY	113
4.2	PHYSICAL AND CHEMICAL PROPERTIES	113
5.	PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL	117
5.1	PRODUCTION	117
5.2	IMPORT/EXPORT	119
5.3	USE	119
5.4	DISPOSAL	123
6.	POTENTIAL FOR HUMAN EXPOSURE	125
6.1	OVERVIEW	125
6.2	RELEASES TO THE ENVIRONMENT	127
6.2.1	Air	127
6.2.2	Water	128
6.2.3	Soil	130
6.3	ENVIRONMENTAL FATE	130
6.3.1	Transport and Partitioning	131
6.3.2	Transformation and Degradation	133
6.3.2.1	Air	133
6.3.2.2	Water	133
6.3.2.3	Sediment and Soil	135
6.3.2.4	Environmental Media	136
6.4	LEVELS MONITORED OR ESTIMATED IN THE ENVIRONMENT	136
6.4.1	Air	136
6.4.2	Water	138
6.4.3	Sediment and Soil	139
6.4.4	Other Environmental Media	140
6.5	GENERAL POPULATION AND OCCUPATIONAL EXPOSURE	142
6.6	EXPOSURES OF CHILDREN	144
6.7	POPULATIONS WITH POTENTIALLY HIGH EXPOSURES	146
6.8	ADEQUACY OF THE DATABASE	147
6.8.1	Identification of Data Needs	148
6.8.2	Ongoing Studies	151
7.	ANALYTICAL METHODS	155
7.1	BIOLOGICAL SAMPLES	155
7.2	ENVIRONMENTAL SAMPLES	158
7.3	ADEQUACY OF THE DATABASE	162
7.3.1	Identification of Data Needs	163
7.3.2	Ongoing Studies	164
8.	REGULATIONS AND ADVISORIES	165
9.	REFERENCES	171
10.	GLOSSARY	221

APPENDICES

A.	ATSDR MINIMAL RISK LEVELS AND WORKSHEETS .....	A-1
B.	USER'S GUIDE .....	B-1
C.	ACRONYMS, ABBREVIATIONS, AND SYMBOLS .....	C-1
D.	INDEX .....	D-1



## LIST OF FIGURES

3-1. Levels of Significant Exposure to Methyl Parathion - Inhalation .....	23
3-2. Levels of Significant Exposure to Methyl Parathion - Oral .....	40
3-3. Proposed Metabolic Pathways of Methyl Parathion .....	73
3-4. Conceptual Representation of a Physiologically Based Pharmacokinetic (PBPK) Model for a Hypothetical Chemical Substance .....	79
3-5. Existing Information on Health Effects of Methyl Parathion .....	101
6-1. Frequency of NPL Sites with Methyl Parathion Contamination .....	126



## LIST OF TABLES

3-1. Levels of Significant Exposure to Methyl Parathion - Inhalation .....	22
3-2. Plasma and Erythrocyte Cholinesterase Levels in Children Intoxicated by Methyl Parathion .....	26
3-3. Levels of Significant Exposure to Methyl Parathion - Oral .....	30
3-4. Levels of Significant Exposure to Methyl Parathion - Dermal .....	57
3-5. Genotoxicity of Methyl Parathion <i>In Vivo</i> .....	63
3-6. Genotoxicity of Methyl Parathion <i>In Vitro</i> .....	64
4-1. Chemical Identity of Methyl Parathion .....	114
5-1. Facilities that Produce, Process, or Use Methyl Parathion .....	118
5-2. Methyl Parathion Use in Crop Production in 1992 .....	121
6-1. Releases to the Environment from Facilities that Produce, Process, or Use Methyl Parathion ...	129
6-2. Ongoing Studies of Methyl Parathion Found in Federal Research in Progress .....	152
7-1. Analytical Methods for Determining Methyl Parathion and Metabolites in Biological Materials .....	156
7-2. Analytical Methods for Determining Methyl Parathion in Environmental Samples .....	159
8-1. Regulations and Guidelines Applicable to Methyl Parathion .....	166